Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s): MDNAF

Healthcare Biotechnology

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

TSX:MDNA - Post by User

Medicenna Therapeutics Corp > Surprised and grateful that MDNA ran up over 2.00

<< Previous

Bullboard Posts

Next >>

Comment by ENEMENEMYNEMOon Apr 28, 2024 8:41am

129 Views

Post# 36011446

RE:RE:RE:RE:Surprised and grateful that MDNA ran up over 2.00

Someone is angry they missed out!! MDNA is successful , meanwhile you are pumping a nothing burger that's been looking for success from the same product for 25 years with no success. Where they have been successful is suckering in investors with false hope draining many of their savings for what 20 clinical trials that went no where!!!

<< Previous

Bullboard Posts

Next >>

AI companies to invest in